Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

被引:7
|
作者
Witjes, J. Alfred [1 ]
Feikema, Astrid A. H. [1 ]
机构
[1] Radboudumc, Dept Urol, Nijmegen, Netherlands
来源
CANCER MANAGEMENT AND RESEARCH | 2021年 / 13卷
关键词
bladder cancer; cystectomy; trimodality treatment; oncological outcome; functional outcome; organ preservation; RADICAL CYSTECTOMY; TRANSURETHRAL RESECTION; OUTCOMES; THERAPY; CHEMOTHERAPY; GUIDELINES; SURGERY;
D O I
10.2147/CMAR.S294099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with significant perioperative and postoperative morbidity and mortality, having short-term complication rates between 14.4% and 21.7%, and long-term oncological survival rates ranging from 60% after 5 years to 43% after 10 years. The impact on quality of life (QoL) in patients after treatment for bladder cancer is significantly worse than in other pelvic cancers. Although RC is strongly recommended as the gold standard, there is a need for bladder-sparing options in MIBC. Attempts to improve mortality and morbidity rates after RC have been made by implementing Enhanced Recovery After Surgery (ERAS), robot-assisted RC, and sexual function-preserving techniques. None of these significantly improves QoL or functional outcome. Because of the invasiveness of RC, other therapeutic options have been evaluated. Transurethral resection of the bladder tumor (TURB) plays an important role in the diagnostic evaluation of MIBC and has also been reviewed as a curative option, although the oncological results appear inferior to RC. Furthermore, improved radiotherapy (RT) and widely used chemotherapy, both as mono therapeutic options in bladder cancer, are not as effective as radical surgery, with lower survival rates. Trimodality treatment (TMT) in bladder cancer combines TURB with chemotherapy and RT. The goal of TMT is preserving the bladder and QoL without compromising oncological outcome. A 2018 review showed no difference in overall survival rates between RC and TMT (30.9% vs 35.1%), with lower survival rates after RC than TMT in the first year of follow-up, probably due to higher postoperative mortality. For a selected group of patients, TMT is to be recommended, and it is the most favorable option out of the organ sparing strategies in MIBC.
引用
收藏
页码:7833 / 7839
页数:7
相关论文
共 50 条
  • [1] Organ-sparing treatment in muscle-invasive bladder cancer
    Dunst, J
    Diestelhorst, A
    Kühn, R
    Müller, AC
    Scholz, HJ
    Fornara, P
    STRAHLENTHERAPIE UND ONKOLOGIE, 2005, 181 (10) : 632 - 637
  • [2] Organ-sparing precision treatment for muscle-invasive bladder cancer
    Li, Roger
    NATURE MEDICINE, 2023, 29 (11) : 2709 - 2710
  • [3] Organ-sparing precision treatment for muscle-invasive bladder cancer
    Roger Li
    Nature Medicine, 2023, 29 : 2709 - 2710
  • [4] Organ-sparing strategies in the management of invasive bladder cancer
    Yafi, Faysal A.
    Cury, Fabio L.
    Kassouf, Wassim
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (12) : 1765 - 1775
  • [5] Radical cystectomy vs organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review
    Arcangeli, S.
    Strigari, L.
    Arcangeli, G.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S354 - S354
  • [6] Organ-Sparing Multimodality Treatment for Muscle-Invasive Bladder Cancer: Can We Continue to Ignore the Evidence?
    Roedel, Claus
    Weiss, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (34) : 3787 - U161
  • [7] Organ-Sparing Treatment in Muscle-Invasive Bladder CancerOrganerhaltende Behandlung des muskelinvasiven Harnblasenkarzinoms
    Jürgen Dunst
    Andrea Diestelhorst
    Reinhard Kühn
    Arndt-Christian Müller
    Hans-Jörg Scholz
    Paolo Fornara
    Strahlentherapie und Onkologie, 2005, 181 : 632 - 637
  • [8] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Matthew D. Galsky
    Siamak Daneshmand
    Sudeh Izadmehr
    Edgar Gonzalez-Kozlova
    Kevin G. Chan
    Sara Lewis
    Bassam El Achkar
    Tanya B. Dorff
    Jeremy Paul Cetnar
    Brock O. Neil
    Anishka D’Souza
    Ronac Mamtani
    Christos Kyriakopoulos
    Tomi Jun
    Mahalya Gogerly-Moragoda
    Rachel Brody
    Hui Xie
    Kai Nie
    Geoffrey Kelly
    Amir Horowitz
    Yayoi Kinoshita
    Ethan Ellis
    Yohei Nose
    Giorgio Ioannou
    Rafael Cabal
    Diane M. Del Valle
    G. Kenneth Haines
    Li Wang
    Kent W. Mouw
    Robert M. Samstein
    Reza Mehrazin
    Nina Bhardwaj
    Menggang Yu
    Qianqian Zhao
    Seunghee Kim-Schulze
    Robert Sebra
    Jun Zhu
    Sacha Gnjatic
    John Sfakianos
    Sumanta K. Pal
    Nature Medicine, 2023, 29 : 2825 - 2834
  • [9] Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies.
    Dumont, Clement
    Gauthier, Helene
    Mongiat-Artus, Pierre
    Masson-Lecomte, Alexandra
    Desgrandchamps, Francois
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
    Galsky, Matthew D.
    Daneshmand, Siamak
    Izadmehr, Sudeh
    Gonzalez-Kozlova, Edgar
    Chan, Kevin G.
    Lewis, Sara
    Achkar, Bassam El
    Dorff, Tanya B.
    Cetnar, Jeremy Paul
    Neil, Brock O.
    D'Souza, Anishka
    Mamtani, Ronac
    Kyriakopoulos, Christos
    Jun, Tomi
    Gogerly-Moragoda, Mahalya
    Brody, Rachel
    Xie, Hui
    Nie, Kai
    Kelly, Geoffrey
    Horwitz, Amir
    Kinoshita, Yayoi
    Ellis, Ethan
    Nose, Yohei
    Ioannou, Giorgio
    Cabal, Rafael
    Haines, G. Kenneth
    Wang, Li
    Mouw, Kent W.
    Samstein, Robert M.
    Mehrazin, Reza
    Bhardwaj, Nina
    Yu, Menggang
    Zhao, Qianqian
    Kim-Schulze, Seunghee
    Sebra, Robert
    Zhu, Jun
    Gnjatic, Sacha
    Sfakianos, John
    Pal, Sumanta K.
    NATURE MEDICINE, 2023, 29 (11) : 2825 - +